Skip to main content
. Author manuscript; available in PMC: 2009 Sep 1.
Published in final edited form as: J Pain Symptom Manage. 2008 Apr 14;36(3):289–303. doi: 10.1016/j.jpainsymman.2007.10.005

Table 1.

Histological & Immunohistochemical qualification of bone remodeling, tumor progression, and neurochemical changes in ibandronate (3 × 100µg/kg cum.) and 2472 + Vehicle treated Mice

Sham + Vehicle 2472 + Vehicle 2472 + Ibanreonate
1. Bone Histomorphometry (Day 14)
  Osteoclasts
  (OC # throughout the intramedullary space)		 193±4 345±70a 323±14a
  Macrophages
  (Ms # throughout the intramedullary space)		 19±2 77±7a 68±2a
  Tumor cells
  (% intramedullary space occupied)		 0±0 100±0a 93±6a
  Hematopoetic Cells
  (% intramedullary space occupied)		 100±0 0±0a 7±4a
2. Immunohistochemistry (Day 14)
  Spinal Cord
    c-Fos (LIII–VI) 8.5±2.8 33±7a,b 7.2±2.4a,b
    Dynorphin (LIII–VI) 2.3±0.6 4.9±0.6a,b 2.3±0.6a,b
    Gilal Fibrillary Acidic Protein (GFAP)
    Expressed as % of Sham Value		 100±11 126±48 112±7
a

P<0.005 versus sham + vehicle (one way ANOVA, Fisher’s PLSD).

b

P<0.005 versus 2472 + vehicle (one way ANOVA, Fisher’s PLSD).